Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

The Lancet

Volumn 394, Issue 10206, 2019, Pages 1352-1363

  Cree, Bruce A C ^a   Bennett, Jeffrey L ^b   Kim, Ho Jin ^c   Weinshenker, Brian G ^d   Pittock, Sean J ^d   Wingerchuk, Dean M ^e   Fujihara, Kazuo ^f,g   Paul, Friedemann ^h,i   Cutter, Gary R ^j   Marignier, Romain ^k   Green, Ari J ^a   Aktas, Orhan ^l   Hartung, Hans Peter ^l   Lublin, Fred D ^m   Drappa, Jorn ⁿ   Barron, Gerard ^o   Madani, Soraya ⁿ   Ratchford, John N ⁿ   She, Dewei ⁿ   Cimbora, Daniel ⁿ   Katz, Eliezer ⁿ   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c National Cancer Center   (South Korea)

^d MAYO CLINIC   (United States)

^e MAYO CLINIC   (United States)

^f FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^g Southern Tohoku General Hospital and Southern Tohoku Research Institute for Neuroscience   (Japan)

^h MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k HOSPICES CIVILS DE LYON   (France)

^l Department of Orthopedic Surgery   (Germany)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ Viela Bio   (United States)

^o MEDIMMUNE LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CETIRIZINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FINGOLIMOD; INEBILIZUMAB; METHOTREXATE; MITOXANTRONE; MIZORIBINE; MYCOPHENOLATE MOFETIL; PENTOXIFYLLINE; PLACEBO; MEDI-551; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BURN; CHOLANGITIS; CHOLECYSTITIS; CONTROLLED STUDY; CYSTITIS; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; EYE PAIN; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; HYPESTHESIA; HYPOGLYCEMIA; INFUSION RELATED REACTION; INTERACTIVE VOICE RESPONSE SYSTEM; LEG PAIN; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MYELITIS; MYELOOPTIC NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SCREENING TEST; SEPTIC SHOCK; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; VIRUS MENINGITIS; VIRUS PNEUMONIA; VISUAL DISORDER; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85072938913     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)31817-3     Document Type: Article

References (28)

1. Cree BA Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica: ethical and design considerations. Mult Scler 2016; 22: 862–72.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–15.
3. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 2012; 3: 58–73.
4. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566–69.
5. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66: 617–29.
6. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158–62.
7. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133: 349–61.
8. Bennett JL, O'Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015; 2: e104.
9. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1–16.
10. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270–72.
11. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016; 73: 1342–48.
12. Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris) 2018; 174: 255–64.
13. Cree BA. Placebo controlled trials in neuromyelitis optica are needed and ethical. Mult Scler Relat Disord 2015; 4: 536–45.
14. Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014; 193: 580–86.
15. Chen D, Gallagher S, Monson NL, Herbst R, Wang Y. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med 2016; 5: 107.
16. Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 2016; 18: 131.
17. Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler 2019; 25: 235–45.
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–89.
19. Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015; 2: e61.
20. Patra K, Cree BAC, Katz E, Pulkstenis E, Dmitrienko A, Cutter G. Statistical considerations for an adaptive design for a serious rare disease. Ther Innov Regul Sci 2016; 50: 375–84.
21. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009; 28: 586–604.
22. Genentech. Rituxan prescribing information. January, 2019. https://www.gene.com/download/pdf/rituxan_prescribing.pdf (accessed Feb 28, 2019).
23. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–88.
24. Genentech. Ocrevus prescribing information. November, 2018. https://www.gene.com/download/pdf/ocrevus_prescribing.pdf (accessed Feb 28, 2019).
25. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221–34.
26. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–20.
27. Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 2018; 27: 265–71.
28. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Eng J Med 2019; published online May 3. DOI:10.1056/NEJMoa1900866.